Document is current
Any future updates will be listed below
-
Authors
Dietzen, Michelle http://orcid.org/0000-0002-6853-7563
Zhai, Haoran http://orcid.org/0000-0002-9418-292X
Lucas, Olivia http://orcid.org/0000-0001-8169-7767
Pich, Oriol http://orcid.org/0000-0002-1956-1882
Barrington, Christopher http://orcid.org/0000-0003-1281-2658
Lu, Wei-Ting http://orcid.org/0000-0002-1405-4806
Ward, Sophia http://orcid.org/0000-0002-6777-5279
Guo, Yanping
Hynds, Robert E. http://orcid.org/0000-0002-2170-8791
Zaccaria, Simone http://orcid.org/0000-0002-5265-7392
Swanton, Charles http://orcid.org/0000-0002-4299-3018
McGranahan, Nicholas http://orcid.org/0000-0001-9537-4045
Kanu, Nnennaya http://orcid.org/0000-0001-7232-1952
-
Funding
Funding for this research was provided by:
Funding information for each author can be found in the Manuscript file.
- License Information
-
More Information
Article History
Received: 7 January 2024
Accepted: 1 July 2024
First Online: 18 July 2024
Competing interests
: N.M. has stock options in and has consulted for Achilles Therapeutics and holds a European patent in determining HLA LOH (PCT/GB2018/052004) and is a co-inventor to a patent to identifying responders to cancer treatment (PCT/GB2018/051912). N.K. acknowledges grant support from AstraZeneca. C.S. acknowledges grant support from AstraZeneca, Boehringer-Ingelheim, Bristol Myers Squibb, Pfizer, Roche-Ventana, Invitae (previously Archer Dx Inc. - collaboration in minimal residual disease sequencing technologies), and Ono Pharmaceutical. He is an AstraZeneca Advisory Board member and Chief Investigator for the AZ MeRmaiD 1 and 2 clinical trials and is also chief investigator of the NHS Galleri trial. He has consulted for Achilles Therapeutics, Amgen, AstraZeneca, Pfizer, Novartis, GlaxoSmithKline, MSD, Bristol Myers Squibb, Illumina, Genentech, Roche-Ventana, GRAIL, Medicxi, Metabomed, Bicycle Therapeutics, Roche Innovation Centre Shanghai, and the Sarah Cannon Research Institute, C.S. had stock options in Apogen Biotechnologies and GRAIL until June 2021, and currently has stock options in Epic Bioscience, Bicycle Therapeutics, and has stock options and is co-founder of Achilles Therapeutics. C.S. holds patents relating to assay technology to detect tumour recurrence (PCT/GB2017/053289); to targeting neoantigens (PCT/EP2016/059401), identifying patent response to immune checkpoint blockade (PCT/EP2016/071471), determining HLA LOH (PCT/GB2018/052004), predicting survival rates of patients with cancer (PCT/GB2020/050221), identifying patients who respond to cancer treatment (PCT/GB2018/051912), US patent relating to detecting tumour mutations (PCT/US2017/28013), methods for lung cancer detection (US20190106751A1) and both a European and US patent related to identifying insertion/deletion mutation targets (PCT/GB2018/051892). The remaining authors declare no competing interests.
